Literature DB >> 12511424

Missense mutation and defective function of ATM in a childhood acute leukemia patient with MLL gene rearrangement.

Kaoru Oguchi1, Masatoshi Takagi, Rika Tsuchida, Yoichi Taya, Etsuro Ito, Keiichi Isoyama, Eiichi Ishii, Laura Zannini, Domenico Delia, Shuki Mizutani.   

Abstract

The possible involvement of germline mutation of the ataxia telangiectasia mutated (ATM) gene in childhood acute leukemia with mixed lineage leukemia (MLL) gene rearrangement (MLL(+)) was investigated. Of the 7 patients studied, 1 showed a germline missense ATM mutation (8921C>T; Pro2974Leu), located in the phosphatidylinositol-3 (PI-3) kinase domain. In reconstitution assays, the ATM mutant 8921T could only partially rescue the radiosensitive phenotype of AT fibroblasts, and in an in vitro kinase assay, it showed a defective phosphorylation of p53-Ser15. Furthermore, the introduction of 8921T in U2OS cells, characterized by a normal ATM/p53 signal transduction, caused a significant reduction of in vivo p53-Ser15 phosphorylation, suggesting a dominant-negative effect of the mutant ATM over the wild-type protein. Our finding in this patient suggests that altered function of ATM plays some pathogenic roles in the development of MLL(+) leukemia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12511424     DOI: 10.1182/blood-2002-02-0570

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  Early G2/M checkpoint failure as a molecular mechanism underlying etoposide-induced chromosomal aberrations.

Authors:  Shinichiro Nakada; Yoko Katsuki; Issei Imoto; Tetsuji Yokoyama; Masayuki Nagasawa; Johji Inazawa; Shuki Mizutani
Journal:  J Clin Invest       Date:  2005-12-15       Impact factor: 14.808

Review 2.  Molecular pathogenesis of MLL-associated leukemias.

Authors:  Mariko Eguchi; Minenori Eguchi-Ishimae; Mel Greaves
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

3.  ATM modulates the loading of recombination proteins onto a chromosomal translocation breakpoint hotspot.

Authors:  Jiying Sun; Yukako Oma; Masahiko Harata; Kazuteru Kono; Hiroki Shima; Aiko Kinomura; Tsuyoshi Ikura; Hidekazu Suzuki; Shuki Mizutani; Roland Kanaar; Satoshi Tashiro
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

4.  Phenotypic variations between affected siblings with ataxia-telangiectasia: ataxia-telangiectasia in Japan.

Authors:  Tomohiro Morio; Naomi Takahashi; Fumiaki Watanabe; Fumiko Honda; Masaki Sato; Masatoshi Takagi; Ken-Ichi Imadome; Toshio Miyawaki; Domenico Delia; Kotoka Nakamura; Richard A Gatti; Shuki Mizutani
Journal:  Int J Hematol       Date:  2009-08-25       Impact factor: 2.490

5.  Bimodal degradation of MLL by SCFSkp2 and APCCdc20 assures cell cycle execution: a critical regulatory circuit lost in leukemogenic MLL fusions.

Authors:  Han Liu; Emily H-Y Cheng; James J-D Hsieh
Journal:  Genes Dev       Date:  2007-10-01       Impact factor: 11.361

Review 6.  MLL fusions: pathways to leukemia.

Authors:  Han Liu; Emily H Y Cheng; James J D Hsieh
Journal:  Cancer Biol Ther       Date:  2009-07       Impact factor: 4.742

Review 7.  Leukemogenic rearrangements at the mixed lineage leukemia gene (MLL)-multiple rather than a single mechanism.

Authors:  Boris Gole; Lisa Wiesmüller
Journal:  Front Cell Dev Biol       Date:  2015-06-25

Review 8.  Novel targets for ATM-deficient malignancies.

Authors:  Johannes Winkler; Kay Hofmann; Shuhua Chen
Journal:  Mol Cell Oncol       Date:  2014-08-13

9.  Molecular variants of the ATM gene in Hodgkin's disease in children.

Authors:  E Liberzon; S Avigad; I Yaniv; B Stark; G Avrahami; Y Goshen; R Zaizov
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

10.  Dysregulation of the DNA Damage Response and KMT2A Rearrangement in Fetal Liver Hematopoietic Cells.

Authors:  Mai Nanya; Masaki Sato; Kousuke Tanimoto; Minoru Tozuka; Shuki Mizutani; Masatoshi Takagi
Journal:  PLoS One       Date:  2015-12-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.